Familial Dysautonomia Completed Phase 3 Trials for Carbidopa (DB00190)

Also known as: Riley-Day syndrome / Dysautonomia, Familial / Familial dysautonomia [Riley-Day] / HSAN III

IndicationStatusPhase
DBCOND0048634 (Familial Dysautonomia)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01212484Carbidopa for the Treatment of Nausea and Vomiting in Familial DysautonomiaTreatment